- Home
- JLS vs GNLX Comparison
JLS vs GNLX Comparison
Compare JLS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | GNLX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.9M | 108.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JLS | GNLX |
|---|---|---|
| Price | $18.57 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 26.6K | ★ 224.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.48 | $1.99 |
| 52 Week High | $17.97 | $8.54 |
Technical Indicators
Market Signals| Indicator | JLS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 37.97 |
| Support Level | $18.67 | $2.36 |
| Resistance Level | $18.94 | $2.69 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 30.58 | 37.20 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.